Hoth Therapeutics Files 8-K: Other Events Reported

TL;DR

HOTH filed an 8-K for 'Other Events' on 9/12/25 - details TBD.

AI Summary

Hoth Therapeutics, Inc. filed an 8-K on September 12, 2025, reporting "Other Events." The filing does not contain specific details about the nature of these events, dollar amounts, or definitive dates beyond the filing date itself.

Why It Matters

This filing indicates that Hoth Therapeutics has reported significant events to the SEC, but the lack of detail requires further investigation to understand the implications for the company.

Risk Assessment

Risk Level: medium — The filing is an 8-K for 'Other Events' without specific details, which can indicate significant but undisclosed developments, warranting a medium risk assessment.

Key Players & Entities

• Hoth Therapeutics, Inc. (company) — Registrant
• September 12, 2025 (date) — Filing Date

FAQ

Key Financial Figures

• $0.0001 — nge on which registered Common stock, $0.0001 par value HOTH The Nasdaq Stock Mar
• $1 million — As such, the Company may purchase up to $1 million in Bitcoin, Ethereum and/or Solana as a

Filing Documents

• ea0257020-8k_hoth.htm (8-K) — 32KB
• 0001213900-25-087054.txt ( ) — 197KB
• hoth-20250912.xsd (EX-101.SCH) — 3KB
• hoth-20250912_lab.xml (EX-101.LAB) — 33KB
• hoth-20250912_pre.xml (EX-101.PRE) — 22KB
• ea0257020-8k_hoth_htm.xml (XML) — 4KB

Risk Factors

Risk Factors The Company is supplementing the risk factors previously disclosed in its Annual Report on Form 10-K for the year ended December 31, 2024 with the following risk factor: Risks Related to the Company Our digital assets strategy exposes us to various risks. Our digital assets strategy exposes us to various risks, including the following: Digital assets are highly volatile assets. The price of digital assets such as Bitcoin, Ethereum and Solana has been volatile and often experiences sharp price movements due to its speculative nature and diverse sentiments of its global investor base. Regulatory changes may further effect such volatility. While the Company's board has approved the purchase up to $1 million in Bitcoin, Ethereum and/or Solana as a treasury reserve asset, the volatility associated with such digital assets may undermine their reliability as a store of value, including its long-term value, which may have a material adverse effect on the Company's financial condition. Bitcoin, Ethereum and Solana do not pay dividends. Bitcoin, Ethereum and Solana do not pay dividends and we can only generate cash from our holdings if we sell our digital assets or implement strategies to create income streams or otherwise generate cash by using our holdings. Even if we pursue any such strategies, we may be unable to create income streams or otherwise generate cash from our holdings, and any such strategies may subject us to additional risks. Our digital assets strategy has not been tested over an extended period of time or under different market conditions. We intend to continually examine the risks and rewards of our strategy to acquire and hold Bitcoin, Ethereum and/or Solana. This strategy has not been tested over an extended period of time or under different market conditions. For example, although we believe Bitcoin, due to its fixed supply, has the potential to serve as a hedge against inflation in the long term, the short-term price of Bitcoin

Forward Looking Statements

Forward Looking Statements This Current Report on Form 8-K includes "forward-looking Report on Form 8-K include, but are not limited to, statements that relate to the Company's potential purchase of Bitcoin, Ethereum and/or Solana as a treasury reserve asset and other information that is not historical information. When used herein, words such as "anticipate", "being", "will", "plan", "may", "continue", and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon the Company's current expectations and various assumptions. The Company believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. The Company may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described under the caption "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, and the Company's other filings made with the Securities and Exchange Commission. Consequently, forward-looking statements should be regarded solely as the Company's current plans, estimates and beliefs. Investors should not place undue reliance on forward-looking undertake and specifically declines any obligation to update, republish, or revise any forw

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: September 12, 2025 Hoth Therapeutics, Inc. /s/ Robb Knie Robb Knie Chief Executive Officer - 3 -

View Full Filing

View this 8-K filing on SEC EDGAR